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A b s t r a c t
Introduction: Prevention of periprocedural stroke has a crucial role in carotid artery stenting (CAS) procedures.
Aim: To assess retrospectively 30-day safety and effectiveness of 41 procedures of internal and common carotid artery stenting 
using the Roadsaver double nitinol layer micromesh stent in 40 non-consecutive patients with symptomatic or high-risk carotid 
artery stenosis.
Material and methods: The patients were men (n = 31) and women (n = 9); mean age was 67.8 ±7.9 years. Femoral access 
was used in 39 cases, whereas radial access was used in 2. Proximal (n = 27) or distal (n = 14) embolic neuroprotection was used.
Results: The Roadsaver stents (nominal diameter 7, 8 or 9 mm, length 25 or 30 mm) were implanted successfully in all cases. 
One minor stroke occurred after common carotid artery intubation with a guiding catheter (before stent deployment) and one 
transient postprocedural ischemic attack (TIA) of the ipsilateral cerebral hemisphere was observed. Internal/common carotid artery 
stenosis severity was evaluated by duplex Doppler. Maximal peak systolic velocity (PSV) before CAS was in the range: 2.0–7.0 m/s, 
mean: 3.9 ±1.0 m/s, at 24–48 h after stenting mean PSV was 1.1 ±0.4 m/s (p < 0.05), and at 30 days 1.1 ±0.3 m/s (p < 0.05). Maximal 
end-diastolic velocity (EDV) was 0.85–3.5 m/s, mean 1.4 ±0.5 m/s, at 24–48 h after stenting mean EDV was 0.3 ±0.1 m/s (p < 0.05), 
and at 30 days 0.4 ±0.1 m/s (p < 0.05). No restenosis or thrombosis was observed. Angiographic stenosis decreased from 82.9 ±9.1% 
(range: 61–97%) to 19.3 ±7.3% (range: 0–34%) (p < 0.05).
Conclusions: The CAS using the Roadsaver stent seems to be safe and effective. Further studies involving larger patient popu-
lations and longer follow-up are needed.
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Introduction
Carotid artery stenting (CAS) is an alternative to surgery, 
and prevention of embolization has a crucial role during the 
CAS procedure. The CREST (Carotid Revascularization End-
arterectomy versus Stenting Trial) trial suggested a higher 
risk of ipsilateral strokes after CAS compared to carotid 
endarterectomy (CEA) by 30 days. In contrast, there was no 
significant difference in the incidence of ipsilateral major 
stroke related to CAS or CEA from 30 days until 4 years [1]. 
With conventional carotid stents, the risk of embolization 
as a result of plaque protrusion persists for 30 consecutive 
days until the stent is endothelialized [2]. The risk of emboli-
sation leading to adverse neurological events is particularly 
high after stent implantation, after postdilatation and after 
embolic protection device (EPD) removal. For this reason, it 
is necessary to refine the carotid stent design [2]. 
Use of closed-cell rather than open-cell design stents 
has been, in general, associated with a  reduction of the 
number of periprocedural adverse neurologic events, par-
ticularly in symptomatic patients [3, 4]. Proper selection of 
patients, the most appropriate EPD and stent type (tailored 
CAS) is necessary to ensure periprocedural safety [5, 6].
One of the recently introduced new stent designs 
is the double nitinol layer micromesh self-expandable 
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stent Roadsaver [1, 2, 7–10]. The stent has a  double 
structure: external macromesh and internal micromesh. 
The smallest cell size is 375–500 µm. The external layer 
crushes the plaque, flattening it to the inner wall of the 
vessel. The internal layer protects against plaque pro-
trusion and embolization thanks to the optimized mi-
cromesh density [1, 7].
Aim
We assessed the safety and effectiveness of percu-
taneous carotid stent implantation using the Roadsaver 
stent in the treatment of symptomatic or high-risk, extra-
cranial carotid artery disease. 
Material and methods
This is a retrospective analysis of 41 procedures us-
ing the Roadsaver stent in non-consecutive symptomatic 
cases (n = 21, 51.2%) and/or in patients with high-risk 
stenosis (n = 20, 48.7%). There were 31 men (age: 68.5 
±8.2 range: 51–84 years) and 9 women (age: 59.6 ±6.2, 
range: 57–72) with significant (> 50% diameter steno-
sis, DS) internal or common carotid artery (ICA or CCA) 
stenosis. One patient with severe, bilateral ICA stenosis 
underwent a sequential CAS procedure of both ICA. High-
risk ICA stenoses were defined as lesions over 25 mm 
in length, containing aneurysm, thrombus or ulceration.
The patients suffered from hypertension (n = 37), hy-
perlipidemia (n = 38), diabetes (n = 13), and coronary 
artery disease (n = 30). Moreover, 10 patients had pre-
vious myocardial infarction, 8 patients had multivessel 
coronary artery disease, and 9 patients had previously 
undergone contralateral carotid artery stenting (Table I). 
Carotid stenosis grade was assessed on carotid Doppler 
duplex ultrasound and it was subsequently verified by 
quantitative carotid angiography (QCA) just before CAS. 
The mean DS was 82.9 ±9.1% (range: 61–97%). The 
length of the stenotic segment was from 20 to 48 mm 
(mean: 27.2 ±6.4 mm). 
Each patient was on dual antiplatelet therapy (aspirin 
75 mg and clopidogrel 75 mg daily for at least 3 days 
before the procedure or loading doses of 300 mg of aspi-
rin and clopidogrel the day before the procedure). During 
CAS unfractionated heparin (100 IU/kg) was used.
We performed 15 procedures of right ICA stenting, 
25 of left ICA stenting and one left common artery angio-
plasty. Proximal (n = 27) or distal (n = 14) embolic protec-
tion was applied. Guiding catheters 7 Fr (n = 2) for right 
radial access, 8 Fr (n = 2) or guiding sheaths 5 Fr (n = 3) 
or 6 Fr (n = 7) were used (Table II).
Table I. Baseline characteristics of patients
Parameter Value
Number of patients 40
Age of all patients [years] 67.8 ±7.9
Age of men [years] 68.5 ±8.2




Active smokers 17 (42.5%)
Coronary artery disease 31 (77.5%)
Previous myocardial infarction 10 (25%)
Multivessel coronary artery disease 8 (20%)
Previous contralateral carotid artery stenting 9 (22.5%)
Previous percutaneous coronary artery  
intervention
14 (35%)
Restenosis after carotid endarterectomy 1 (2.5%)
Chronic renal failure 13 (32.5%)
Peripheral artery disease 9 (22.5%)
Transient ischemic attack of ipsilateral  
hemisphere in the last 6 months
1 (2.4%)
Stroke of ipsilateral hemisphere in the last  
6 months
18 (44%)
Ipsilateral amaurosis fugax in the last 6 months 2 (4.8%)
High-risk lesion 20 (48.7%)
Table II. Devices used during carotid stenting with 
Roadsaver stents
Guiding catheters:
– Softip XF 7 Fr (n = 2) for radial access
– Mach Peripheral 8 Fr (n = 1)
– HSII 8 Fr (n = 1)
Guiding sheaths:
– Terumo Destination 5 Fr (n = 3)
– Terumo Destination 6 Fr (n = 7)
Proximal embolic protection 
devices:
– MonoMo.Ma 8 Fr (n = 1)
– Mo.Ma 8Fr (n = 25)
– Mo.Ma 9 Fr (n = 1)
Distal embolic protection 
devices:
– Wirion system (n = 5)
– Emboshield NAV6 (n = 3)
– Spider FX (n = 5)
– Filter Wire EZ (n = 1)
Predilatation:
Sizes of balloon catheter: 2.5–3.5 mm width diameter, mean: 
2.9 ±0.3, 15–20 mm length diameter, mean: 18.1 ±1.0 mm
Inflation pressure: 10–16 atm, mean: 13.0 ±1.5 atm
Sizes of Roadsaver stents:
– 7.0 mm width × 25 mm length diameter (n = 11)
– 8.0 mm width × 25 mm length diameter (n = 12)
– 8.0 mm width × 30 mm length diameter (n = 11)
– 9.0 mm width × 30 mm length diameter (n = 7)
Postdilatation:
Sizes of balloon catheter: 4.5–6.5 mm width diameter, mean: 
4.8 ±0.3 mm, 20 mm length diameter
Inflation pressure: 8–18 atm, mean: 13.07 ±2.5 atm
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Direct stenting was performed in 24 (58.5%) cases, 
whereas in 17 (41.4%) cases predilatation with a small 
coronary balloon (2.5–3.5 mm) was required. In all cas-
es postdilatation was performed using usually 4.5 to 
5.5 mm diameter balloons (in one case 6.5 mm – during 
left common artery angioplasty) to optimize the angio-
graphic outcome (Figures 1, 2). In each patient angiog-
raphy of intracranial arteries before and comparatively 
after the procedure was performed. 
Patients were discharged 1–2 days after the proce-
dure with the recommendation to take aspirin indefinite-
ly and clopidogrel 75 mg for 3 months. In addition, in 
Figure 2. Severe symptomatic lesion of the left ICA and the next steps of CAS using the Roadsaver stent and 
distal EPD-Wirion: A – angiography, B – opening of the filter distal to the ICA stenosis (arrow), C – predilatation, 
D – stent placement, E – stent implantation, F – postdilatation, G – final angiography
A B C D E F G
Figure 1. Severe, high-risk (aneurysm with thrombus) lesion of right ICA and the next steps of CAS using the 
Roadsaver stent and Mo.Ma EPD system: A – angiography, B – Mo.Ma balloons inflated in external and com-
mon carotid artery, C – stent placement, D – stent expanding – “direct stenting”, E – postdilatation, F – final 
angiography
A B C D E F
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4 patients with atrial fibrillation vitamin K antagonists 
were continued after CAS.
Statistical analysis
The data were analyzed using the Statistica 12.0 
software suite (StatSoft). The Shapiro-Wilk W  test and 
the Kolmogorov-Smirnov test with the Lilliefors correc-
tion were used to verify the normality of distribution 
of results. Depending on the result of the normality of 
distribution, the data were analyzed using parametric or 
non-parametric tests. The null hypothesis (H0) was re-
jected at the established level α lower than 0.05. 
Results
The Roadsaver stent was successfully delivered and 
expanded in all cases. One minor stroke occurred directly 
after common carotid artery intubation. In another pa-
tient transient ischemic attack (TIA) of the cerebral hemi-
sphere ipsilateral to the ICA lesion was observed after 
the CAS procedure.
The postprocedural residual stenosis was 0–33% by 
in-house QCA (mean: 19.3 ±7.3%) vs. 82.9 ±9.1% (range: 
61–97%) before the procedure (p < 0.05). No stent 
thrombosis occurred by 30 days. The mean time of the 
procedure was 26 ±6 (range: 18–32) min when proximal 
EPD was used, and for distal embolic protection the time 
of the procedure was 25 ±2 (range: 17–30) min. Fluoros-
copy time was 9.8 ±1.1 (range: 8.1–11.7) min. 
Postprocedural carotid Doppler duplex was per-
formed at 24–48 h after CAS and showed that mean 
peak systolic velocity (PSV) decreased from 3.9 ±1.0 m/s 
(range: 2.0–7.0 m/s) to 1.1 ±0.4 m/s (range: 0.5–2.1 
m/s) (p < 0.05) and at 30-day follow-up mean PSV was 
1.1 ±0.3 m/s (range: 0.7–2.7 m/s) (p < 0.05). Mean 
EDV at 24–48 h after CAS decreased from 1.4 ±0.5 m/s 
(range: 0.85–3.5 m/s) to 0.3 ±0.1 m/s (range: 0.17–0.6) 
(p < 0.05) and at 30-day follow-up mean end-diastol-
ic velocity (EDV) was 0.4 ±0.1 m/s (range: 0.2–0.6) 
(p < 0.05). No significant in-stent restenosis was ob-
served up to 30 days.
Discussion
The micromesh double-layer self-expandable stent 
Roadsaver seems to be a  significant step in the intra-
procedural as well as postprocedural prevention of 
stroke. This particular type of stent is a part of new fam-
ily of double-layered stents [1, 2, 7–10].
The Roadsaver stent combines the advantages of 
open-and closed-cell stents. Open-cell stents may cause 
fibrous cap rupture, plaque protrusion through the struts 
and higher risk of embolization, but they have better 
apposition to the vessel wall than the closed-cell stents. 
However, they have the advantage of good conformabil-
ity in tortuous anatomies [2, 11, 12]. Although conven-
tional carotid stents of closed-cell design may reduce the 
risk of plaque protrusion-associated adverse neurologi-
cal events [3, 4, 13], this risk is not totally eliminated as 
the free cell area is at least 1.08 mm2. 
Schnaudigel et al. showed that significant, ipsilateral 
changes in diffusion-weighted magnetic resonance imag-
ing of the brain are more frequent after CAS with open-
cell stent than after closed-cell stent implantation (p < 
0.01) [14]. Among currently available carotid stents, the 
closed-cell Carotid Wallstent has the smallest size of cells 
(it covers the plaque and decreases the risk of plaque 
protrusion through the struts). However, due to the low 
flexibility of this stent type, stent delivery in a tortuous 
vessel may be difficult [1, 2].
In the last few years, a  new type of carotid stent, 
which combines optimal flexibility with embolic pre-
vention, was developed. The dual-layer micromesh de-
sign and small cell size enable the plaque to be covered 
and possible debris to be “trapped’’ between the stent 
scaffold and the vessel wall. Another important feature 
of the Roadsaver stent is its flexibility, which makes the 
stent deliverable even in tortuous vessels, compared to 
the commonly used closed-cell stents such as the Carot-
id Wallstent or Xact [2, 12]. Recently published data on 
optical coherence tomography imaging of the Roadsaver 
stent showed good wall apposition without significant 
plaque protrusion through stent cells [1, 15].
The Roadsaver stent has other important aspects: it is 
fully re-sheathable and repositionable even after deploy-
ing 50% of the stent’s length, has a 5 Fr rapid exchange 
delivery system and a  low profile, which enhances the 
crossability. One macro-mesh cell consists of 16 very small 
micromesh cells (size of 0.381 mm²) [1]. The micromesh 
cells are expected to prevent plaque protrusion and em-
bolization after stent implantation. The Roadsaver stent 
has the advantages of both open-cell (flexibility) and 
closed-cell (plaque coverage) stents. The stent is avail-
able from 5 to 10 mm width diameter and 22 to 47 mm 
overall stent length and can accommodate vessels 1 or 
2 mm smaller in diameter than unconstrained conditions 
– maximal length 67 mm. In case of suboptimal stent 
deployment, repositioning is feasible. 
Some authors believe that CAS using the Roadsav-
er stent could be performed without EPD [2, 3, 16]. This 
idea seems to be unreasonable, as periprocedural stroke 
can occur not only during stent implantation, but also at 
the level of introduction of the balloon catheter or stent 
in the unprotected diffusely diseased atherosclerotic ar-
tery. That might have been the possible cause of stroke 
in one of the patients in our study. Another important 
aspect of the micromesh double layer stent is the fact 
that, due to its specific design it can have an important 
role in the treatment of the extracranial carotid artery 
aneurysm or pseudoaneurysm. The unique features of 
micromesh can result in significant reduction of aneu-
rysmal sac perfusion and later complete occlusion within 
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11–17 days only, while the time to full occlusion of the 
aneurysm using other carotid stents is significantly lon-
ger – at least 6 months [8].
The introduction of mesh-covered stents might lead 
to further reduction of the rate of periprocedural neuro-
logical complications of CAS procedures, which is now at 
the level of 2.38% (thirty-day complication rate) accord-
ing to the ‘tailored-CAS’ registry [5, 6], performed in our 
high-volume center. 
Another recently introduced micromesh design – the 
CGuard MicroNet-covered embolic prevention carotid 
stent system (MN-EPS) – gives similar favorable results 
within 30 days. Musialek et al. performed 101 CAS proce-
dures in symptomatic (54.4%) or asymptomatic (45.6%) 
cases. Only 1 symptomatic patient (0.9%) suffered from 
minor ipsilateral stroke 24–48 h after CAS [17]. The reg-
istry of the CGuard stent by Shofer et al. revealed 30 CAS 
procedures. Possible neurological events were assessed 
not only by clinical symptoms (no complications were 
observed) but also on diffusion-weighted magnetic res-
onance imaging (DWI) at 48 h and 30 days after the 
procedure [10]. New ipsilateral minor ischemic lesions at 
48 h occurred in 37% of patients (the average lesion 
volume was 0.39 ±0.08  cm3). The 30-day DWI showed 
complete resolution of all but 1 periprocedural lesion and 
only 1 new minor lesion in relation to the 48-hour scan. 
The recently published CLEAR-ROAD (CAS with the 
Roadsaver stent use) study, which included 100 patients, 
31% symptomatic and EPD use was not mandatory (only 
58% of patients underwent CAS with EPD), showed a low 
major periprocedural adverse event rate of 2.1% [16].
In our study patients were symptomatic or were at 
high risk of neurological embolic complications. Despite 
these unfavorable characteristics, a periprocedural event 
(minor stroke) occurred only in one patient during CAS, 
and it was not related to the Roadsaver because it oc-
curred before stent deployment.
Conclusions
The CAS with the double-layer nitinol Roadsaver stent 
is effective and appears safe. Prospective studies involv-
ing larger numbers of consecutive patients are needed to 
fully demonstrate the benefit of Roadsaver in relation to 
conventional carotid stents. 
Conflict of interest
Dr P. Pieniążek has received honoraria as a  proctor 
from Terumo. Other authors declare no conflict of interest.
References
1. Cremonesi A, Castriota F, Secco GG, et al. Carotid artery stenting: 
an update. Eur Heart J 2014; 36: 13-21.
2. Hopf-Jensen S, Marques L, Preiss M, et al. Initial clinical experi-
ence with the micromesh roadsaver carotid artery stent for the 
treatment of patients with symptomatic carotid artery disease. 
J Endovasc Ther 2015; 22: 220-5. 
3. De Donato G, Setacci C, Deloose K, et al. Long term results of 
carotid atery stenting. J Vasc Surg 2008; 48: 1431-41.
4. Bosiers M, de Donato G, Deloose K, et al. Does free cell area 
influence the outcome in carotid artery stenting? Eur J Vasc 
Endovasc Surg 2007; 33: 135-41.
5. Pieniążek P, Tekieli L, Musialek P, et al. Carotid artery stenting 
according to the tailored CAS algorithm is associated with a low 
complication rate at 30 days: data from the TARGET-CAS study. 
Kardiol Pol 2012; 70: 378-86.
6. Dzierwa K, Pieniążek P, Tekieli L, et al. Carotid artery stenting 
according to the “tailored CAS” algorithm performed in the very 
elderly patients: the thirty day outcome. Catheter Cardiovasc 
Interv 2013; 82: 681-8.
7. Kedev S, Petkoska D, Zafirowska B, et al. Safety of slender 5Fr 
transradial approach for carotid artery stenting with a  novel 
double-layer  micromesh stent. Am J Cardiol 2015; 116: 977-81. 
8. Kabbasch C, Bangard C, Liebig T, et al. The dual layer Casper mi-
cromesh stent: taking advantage of flow-diverting capabilities 
for the treatment of extracranial aneurysm and pseudoaneu-
rysms. Cardiovasc Intervent Radiol 2016; 39: 472-6.
9. Wisgot C, Schmidt W, Brandt C, et al. Preliminary clinical results 
and mechanial behavior of a  new double-layer carotid stent. 
Endovasc Ther 2015; 22: 634-9.
10. Schofer J, Musiałek P, Bijuklic K, et al. A  prospective, multi-
center study of a novel mesh-covered carotid stent: The CGuard 
CARENET Trial (Carotid Embolic Protection Using MicroNet). JACC 
Cardiovasc Interv 2015; 8: 1229-34.
11. Conti M, Van Loo D, Auricchio F, et al. Impact of carotid stent 
cell design on vessel scaffolding: a  case study comparing ex-
perimental investigation and numerical simulations. J Endovasc 
Ther 2011; 18: 397-406.
12. Müller-Hülsbeck S, Preuss H, Elhöft H. CAS: which stent for 
which lesion. J Cardiovasc Surg (Torino) 2009; 50: 767-72.
13. Bosiers M, Deloose K, Verbist J, Peeters P. Carotid artery stent-
ing: which stent for which lesion? Vascular 2005; 13: 205-10.
14. Schnaudigel S, Groschel K, Pilgrom SM, et al. New brain lesions 
after carotid tenting versus carotid endarterectomy: a systemic 
review of the literature. Stroke 2008; 39: 1911-9. 
15. de Donato G, Setacci C, Umemoto T, Reimers B. Inside of the 
interaction between plaque and the stent: optical coherence 
tomography during carotid stentig. J Endovasc Ther 2015; 22: 
950-1.
16. Bosiers M, Deloose K, Torsello G, et al. The CLEAR-ROAD study: 
evaluation of a new dual layer micromesh stent system for the 
carotid artery. EuroIntervention 2016; 12: e671-6.
17. Musialek P, Mazurek A, Trystuła M, et al. Novel paradigm in 
carotid revascularisation: prospective evaluation of all-comer 
percutaneous carotid revascularisation in symptomatic and 
increased-risk asymptomatic carotid artery stenosis using 
CGuardTM MicroNet-covered embolic prevention stent system. 
EuroIntervention 2016; 12: e658-70.
